Exhibit 10.11


 





LOAN AND
SECURITY AGREEMENT


 


THIS LOAN AND
SECURITY AGREEMENT is made and dated as of August 28, 2014 and is entered into by and between EDGE THERAPEUTICS, INC., a
Delaware corporation (“Borrower”), the several banks and other financial institutions or entities from time to time
parties to this Agreement (collectively, referred to as “Lender”) and HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a
Maryland corporation, in its capacity as administrative agent for itself and Lender (in such capacity, the
“Agent”).


 


RECITALS


 


A.         Borrower has
requested Lender to make available to Borrower three (3) term loans (each a “Term Loan Advance” and collectively the
“Term Loan Advances”) in an aggregate principal amount of up to Ten Million Dollars ($10,000,000) (the “Maximum
Term Loan Amount”); and


 


B.         Lender is willing
to make the Term Loan Advances on the terms and conditions set forth in this Agreement.


 


AGREEMENT


 


NOW, THEREFORE, Borrower,
Agent and Lender agree as follows:


 


SECTION
1.            
DEFINITIONS AND RULES OF CONSTRUCTION


 


1.1        
Unless otherwise defined herein, the following capitalized terms shall have the following meanings:


 


“Account Control Agreement(s)”
means any agreement entered into by and among Agent, Borrower and a third party Bank or other institution (including a Securities
Intermediary) in which Borrower maintains a Deposit Account or an account holding Investment Property and which grants Agent a
perfected first priority security interest in the subject account or accounts.


 


“ACH Authorization” means the
ACH Debit Authorization Agreement in substantially the form of Exhibit H.


 


“ACH Failure” means the failure
of the Automated Clearing House (ACH) system to effect a transfer of the funds due to an administrative error in connection with
the institution and execution of the ACH Authorization.


 


“Advance(s)” means a Term Loan
Advance.


 


“Advance Date” means the funding
date of any Advance.


 


“Advance Request” means a request
for an Advance submitted by Borrower to Agent in substantially the form of Exhibit A.


 


“Agent” has the meaning given
to it in the preamble to this Agreement.


 


“Agreement” means this Loan and
Security Agreement, as amended from time to time.


 



    	 



    	 



    




“Amortization Date” means October
1, 2015.


 


“Assignee” has the meaning given
to it in Section 11.13.


 


“Board” means Borrower’s
board of directors.


 


“Borrower Products” means all
products, software, service offerings, technical data or technology currently being designed, manufactured or sold by Borrower
or which Borrower intends to sell, license, or distribute in the future including any products or service offerings under development,
collectively, together with all products, software, service offerings, technical data or technology that have been sold, licensed
or distributed by Borrower since its incorporation.


 


“Business Day” means any day other
than Saturday, Sunday and any other day on which banking institutions in the State of California are closed for business.


 


“Cash” means all cash and liquid
funds.


 


“Change in Control” means any
reorganization, recapitalization, consolidation or merger (or similar transaction or series of related transactions) of Borrower
or any Subsidiary, sale or exchange of outstanding shares (or similar transaction or series of related transactions) of Borrower
or any Subsidiary in which the holders of Borrower or Subsidiary’s outstanding shares immediately before consummation of
such transaction or series of related transactions do not, immediately after consummation of such transaction or series of related
transactions, retain shares representing more than fifty percent (50%) of the voting power of the surviving entity of such transaction
or series of related transactions (or the parent of such surviving entity if such surviving entity is wholly owned by such parent),
in each case without regard to whether Borrower or Subsidiary is the surviving entity, provided that none of the following shall
constitute a Change in Control: (i) any consolidation or merger effected exclusively to change the domicile of Borrower, (ii) an
Initial Public Offering, or (iii) the sale and issuance by the Borrower of its equity securities to investors in a bona fide equity
financing.


 


“Claims” has the meaning given
to it in Section 11.10.


 


“Closing Date” means the date
of this Agreement.


 


“Collateral” means the property
described in Section 3.


 


“Confidential Information” has
the meaning given to it in Section 11.12.


 


“Contingent Obligation” means,
as applied to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to (i) any Indebtedness,
lease, dividend, letter of credit or other obligation of another, including any such obligation directly or indirectly guaranteed,
endorsed, co-made or discounted or sold with recourse by that Person, or in respect of which that Person is otherwise directly
or indirectly liable; (ii) any obligations with respect to undrawn letters of credit, corporate credit cards or merchant services
issued for the account of that Person; and (iii) all obligations arising under any interest rate, currency or commodity swap agreement,
interest rate cap agreement, interest rate collar agreement, or other agreement or arrangement designated to protect a Person against
fluctuation in interest rates, currency exchange rates or commodity prices; provided, however, that the term “Contingent
Obligation” shall not include endorsements for collection or deposit in the ordinary course of business. The amount of any
Contingent Obligation shall be deemed to be an amount equal to the stated or determined amount of the primary obligation in respect
of which such Contingent Obligation is made or, if not stated or determinable, the maximum reasonably anticipated liability in
respect thereof as determined by such Person in good faith; provided, however, that such amount shall not in any event exceed the
maximum amount of the obligations under the guarantee or other support arrangement.


 


“Copyright License” means any
written agreement granting any right to use any Copyright or Copyright registration, now owned or hereafter acquired by Borrower
or in which Borrower now holds or hereafter acquires any interest.


 


“Copyrights” means all copyrights,
whether registered or unregistered, held pursuant to the laws of the United States, any State thereof, or of any other country.


 



    	2



    	 



    




“Deposit Accounts” means any “deposit
accounts,” as such term is defined in the UCC, and includes any checking account, savings account, or certificate of deposit.


 


“Domestic Subsidiary” means any
Subsidiary that is not a Foreign Subsidiary.


 


“End
of Term Charge” means a charge equal to one and one half of one percent (1.50%) of the aggregate original principal amount
of all Term Loan Advances extended by Agent.


 


“Equity Rights Letter Agreement”
means the Equity Rights Letter Agreement dated as of even date hereof by and between Agent and Borrower.


 


“ERISA” means the Employee Retirement
Income Security Act of 1974, as amended, and the regulations promulgated thereunder.


 


“Event of Default” has the meaning
given to it in Section 9.


 


“Facility Charge” means one percent
(1.0%) of the Maximum Term Loan Amount.


 


“Financial Statements” has the
meaning given to it in Section 7.1.


 


“First Draw Period” means the
period commencing upon the occurrence of the First Milestone Event and ending on the earlier to occur of (i) October 15, 2014,
and (ii) an Event of Default.


 


“First Milestone Event” means
confirmation by Agent that Borrower has received, after July 21, 2014, but on or prior to October 15, 2014, unrestricted and unencumbered
gross cash proceeds in an amount of equal to or greater than Fifteen Million Dollars ($15,000,000) from the issuance and sale by
Borrower of its equity securities and/or Subordinated Indebtedness in a transaction or a series of transactions in each case with
Borrower’s existing investors and investors reasonably acceptable to Agent.


 


“Foreign Subsidiary” means any
Subsidiary other than a Subsidiary organized under the laws of any state within the United States.


 


“GAAP” means generally accepted
accounting principles in the United States of America, as in effect from time to time.


 


“Indebtedness” means indebtedness
of any kind, including (a) all indebtedness for borrowed money or the deferred purchase price of property or services (excluding
trade credit entered into in the ordinary course of business due within (i) one hundred twenty (120) days for Evonik Industries,
Wolf Samson, MPI Research, Hyman Phelps, Greenberg Traurig, and Dechert LLP, and (ii) sixty (60) days for all other creditors),
including reimbursement and other obligations with respect to surety bonds and letters of credit, (b) all obligations evidenced
by notes, bonds, debentures or similar instruments, (c) all capital lease obligations as defined by GAAP on the date hereof, and
(d) all Contingent Obligations.


 


“Initial Public Offering” means
the initial firm commitment underwritten offering of Borrower’s common stock pursuant to a registration statement under the
Securities Act of 1933 filed with and declared effective by the Securities and Exchange Commission.


 


“Insolvency Proceeding” is any
proceeding by or against any Person under the United States Bankruptcy Code, or any other bankruptcy or insolvency law, including
assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization,
arrangement, or other similar relief.


 



    	3



    	 



    




“Intellectual Property” means
all of Borrower’s Copyrights; Trademarks; Patents; Licenses; trade secrets and inventions; mask works; Borrower’s applications
therefor and reissues, extensions, or renewals thereof; and Borrower’s goodwill associated with any of the foregoing, together
with Borrower’s rights to sue for past, present and future infringement of Intellectual Property and the goodwill associated
therewith.


 


“Investment” means any beneficial
ownership (including stock, partnership or limited liability company interests) of or in any Person, or any loan, advance or capital
contribution to any Person or the acquisition of all, or substantially all, of the assets of another Person.


 


“Joinder Agreements” means for
each Subsidiary, a completed and executed Joinder Agreement in substantially the form attached hereto as Exhibit G.


 


“Lender” has the meaning given
to it in the preamble to this Agreement.


 


“License” means any Copyright
License, Patent License, Trademark License or other license of rights or interests.


 


“Lien” means any mortgage, deed
of trust, pledge, hypothecation, assignment for security, security interest, encumbrance, levy, lien or charge of any kind, whether
voluntarily incurred or arising by operation of law or otherwise, against any property, any conditional sale or other title retention
agreement, and any lease in the nature of a security interest.


 


“Loan” means the Advances made
under this Agreement.


 


“Loan Documents” means this Agreement,
the Notes (if any), the ACH Authorization, the Account Control Agreements, the Joinder Agreements, all UCC Financing Statements,
the Warrant, the Equity Rights Letter Agreement, any subordination agreement, and any other documents executed in connection with
the Secured Obligations or the transactions contemplated hereby, as the same may from time to time be amended, modified, supplemented
or restated.


 


“Material Adverse Effect” means
a material adverse effect upon: (i) the business, operations, properties, assets, prospects or condition (financial or otherwise)
of Borrower; or (ii) the ability of Borrower to perform the Secured Obligations in accordance with the terms of the Loan Documents,
or the ability of Agent or Lender to enforce any of its rights or remedies with respect to the Secured Obligations; or (iii) the
Collateral or Agent’s Liens on the Collateral or the priority of such Liens.


 


“Maximum Term Loan Amount” shall
have the meaning assigned to such term in the preamble to this Agreement.


 


“Maximum Rate” shall have the
meaning assigned to such term in Section 2.2.


 


“Note(s)” means a promissory note
or promissory notes to evidence Agent’s Loans.


 


“Patent License” means any written
agreement granting any right with respect to any invention on which a Patent is in existence or a Patent application is pending,
in which agreement Borrower now holds or hereafter acquires any interest.


 


“Patents” means all letters patent
of, or rights corresponding thereto, in the United States or in any other country, all registrations and recordings thereof, and
all applications for letters patent of, or rights corresponding thereto, in the United States or any other country.


 



    	4



    	 



    




“Permitted Indebtedness” means:
(i) Indebtedness of Borrower in favor of Lender or Agent arising under this Agreement or any other Loan Document; (ii) Indebtedness
existing on the Closing Date which is disclosed in Schedule 1A; (iii) Indebtedness of up to $500,000 outstanding at any time secured
by a Lien described in clause (vii) of the defined term “Permitted Liens,” provided such Indebtedness does not exceed
the lesser of the cost or fair market value of the Equipment financed with such Indebtedness (determined as of the date on which
such Equipment is financed); (iv) Indebtedness to trade creditors incurred in the ordinary course of business, including Indebtedness
incurred in the ordinary course of business with corporate credit cards; (v) Indebtedness that also constitutes a Permitted Investment;
(vi) Subordinated Indebtedness; (vii) reimbursement obligations in connection with letters of credit that are secured by cash or
cash equivalents and issued on behalf of Borrower or a Subsidiary thereof in an amount not to exceed $200,000 at any time outstanding,
(viii) other Indebtedness in an amount not to exceed $100,000 at any time outstanding, and (ix) extensions, refinancings and renewals
of any items of Permitted Indebtedness, provided that the principal amount is not increased or the terms modified to impose materially
more burdensome terms upon Borrower or its Subsidiary, as the case may be.


 


“Permitted Investment” means:
(i) Investments existing on the Closing Date which are disclosed in Schedule 1B; (ii) (a) marketable direct obligations issued
or unconditionally guaranteed by the United States of America or any agency or any State thereof maturing within one year from
the date of acquisition thereof, (b) commercial paper maturing no more than one year from the date of creation thereof and currently
having a rating of at least A-2 or P-2 from either Standard & Poor’s Corporation or Moody’s Investors Service,
(c) certificates of deposit issued by any bank with assets of at least $500,000,000 maturing no more than one year from the date
of investment therein, and (d) money market accounts; (iii) repurchases of stock from former employees, directors, or consultants
of Borrower under the terms of applicable repurchase agreements at the original issuance price of such securities in an aggregate
amount not to exceed $250,000 in any fiscal year, provided that no Event of Default has occurred, is continuing or would exist
after giving effect to the repurchases; (iv) Investments accepted in connection with Permitted Transfers; (v) Investments (including
debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent
obligations of, and other disputes with, customers or suppliers arising in the ordinary course of Borrower’s business; (vi)
Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who
are not affiliates, in the ordinary course of business, provided that this subparagraph (vi) shall not apply to Investments of
Borrower in any Subsidiary; (vii) Investments consisting of loans not involving the net transfer on a substantially contemporaneous
basis of cash proceeds to employees, officers or directors relating to the purchase of capital stock of Borrower pursuant to employee
stock purchase plans or other similar agreements approved by Borrower’s Board; (viii) Investments consisting of travel advances
and Investments consisting of employee relocation loans and other employee loans and advances not to exceed $50,000 in the aggregate,
and in each case in the ordinary course of business; (ix) Investments in newly-formed Domestic Subsidiaries, provided that each
such Domestic Subsidiary enters into a Joinder Agreement promptly after its formation by Borrower and execute such other documents
as shall be reasonably requested by Agent; (x) Investments in Foreign Subsidiaries approved in advance in writing by Agent; (xi)
joint ventures or strategic alliances in the ordinary course of Borrower’s business consisting of the nonexclusive licensing
of technology, the development of technology or the providing of technical support, provided that any cash Investments by Borrower
do not exceed $500,000 in the aggregate in any fiscal year; and (xii) additional Investments that do not exceed $250,000 in the
aggregate.


 


“Permitted Liens” means any and
all of the following: (i) Liens in favor of Agent or Lender; (ii) Liens existing on the Closing Date which are disclosed in Schedule
1C; (iii) Liens for taxes, fees, assessments or other governmental charges or levies, either not delinquent or being contested
in good faith by appropriate proceedings; provided, that Borrower maintains adequate reserves therefor to the extent required by
GAAP; (iv) Liens securing claims or demands of materialmen, artisans, mechanics, carriers, warehousemen, landlords and other
like Persons arising in the ordinary course of Borrower’s business and imposed without action of such parties; provided,
that the payment thereof is not yet delinquent; (v) Liens arising from judgments, decrees or attachments in circumstances
which do not constitute an Event of Default hereunder; (vi) the following deposits, to the extent made in the ordinary course
of business: deposits under worker’s compensation, unemployment insurance, social security and other similar laws, or to
secure the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure indemnity, performance
or other similar bonds for the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to
secure statutory obligations (other than Liens arising under ERISA or environmental Liens) or surety or appeal bonds, or to secure
indemnity, performance or other similar bonds; (vii) Liens on Equipment or software or other intellectual property constituting
purchase money Liens and Liens in connection with capital leases securing Indebtedness permitted in clause (iii) of “Permitted
Indebtedness” with respect to such Equipment with a fair market value (determined as of the date on which such Equipment
is financed) not in excess of $500,000 outstanding at any time; (viii) Liens incurred in connection with Subordinated Indebtedness;
(ix) leasehold interests in leases or subleases and licenses granted in the ordinary course of business and not interfering in
any material respect with the business of the licensor; (x) Liens in favor of customs and revenue authorities arising as a matter
of law to secure payment of custom duties that are promptly paid on or before the date they become due; (xi) Liens on insurance
proceeds securing the payment of financed insurance premiums that are promptly paid on or before the date they become due (provided
that such Liens extend only to such insurance proceeds and not to any other property or assets); (xii) statutory and common law
rights of set-off and other similar rights as to deposits of cash and securities in favor of banks, other depository institutions
and brokerage firms; (xiii) easements, zoning restrictions, rights-of-way and similar encumbrances on real property imposed by
law or arising in the ordinary course of business so long as they do not materially impair the value or marketability of the related
property; (xiv) Liens on cash or cash equivalents securing obligations permitted under clause (vii) of the definition of Permitted
Indebtedness; and (xv) Liens incurred in connection with the extension, renewal or refinancing of the Indebtedness secured by Liens
of the type described in clauses (i) through (xi) above; provided, that any extension, renewal or replacement Lien shall be
limited to the property encumbered by the existing Lien and the principal amount of the Indebtedness being extended, renewed or
refinanced (as may have been reduced by any payment thereon) does not increase.


 



    	5



    	 



    




“Permitted Transfers” means (i)
sales of Inventory in the ordinary course of business, (ii) licenses and similar arrangements for the use of Intellectual Property
and licenses that could not result in a legal transfer of title of the licensed property but that may be exclusive in respects
other than territory and that may be exclusive as to territory only as to discrete geographical areas outside of the United States,
in each case in the ordinary course of business, or (iii) dispositions of worn-out, obsolete or surplus Equipment at fair market
value in the ordinary course of business, (iv) other Transfers of assets having a fair market value of not more than $250,000 in
the aggregate in any fiscal year, (v) dispositions of the type described in and expressly permitted under Section 7.7, and (vi)
dispositions arising from the abandonment of fixtures and other similar tenant improvements in connection with office relocations
in the ordinary course of business.


 


“Person” means any individual,
sole proprietorship, partnership, joint venture, trust, unincorporated organization, association, corporation, limited liability
company, institution, other entity or government.


 


“Prepayment Charge”
shall have the meaning assigned to such term in Section 2.4.


 


“Prime Rate” means the “prime
rate” as reported in The Wall Street Journal, and if not reported, then the prime rate most recently reported in The Wall
Street Journal.


 


“Receivables” means (i) all of
Borrower’s Accounts, Instruments, Documents, Chattel Paper, Supporting Obligations, letters of credit, proceeds of any letter
of credit, and Letter of Credit Rights, and (ii) all customer lists, software, and business records related thereto.


 


“Required Lenders” means at any
time, the holders of more than 50% of the sum of the aggregate unpaid principal amount of the Term Loan Advances then outstanding.


 


“Second Draw Period” means the
period commencing after March 31, 2015 and upon the occurrence of the First Milestone Event and the Second Milestone Event and
ending on the earlier to occur of (i) June 30, 2015, and (ii) an Event of Default.


 


“Second Milestone Event” means
confirmation by Agent in Agent’s sole and absolute discretion, that on or prior to June 30, 2015, one (1) of the following
milestones has been achieved: (a) delivery by Borrower to Agent of (i) confirmation from the U.S Food and Drug Administration that
Borrower’s “NEWTON” clinical trial results support the advancement of Borrower’s EG-1962 product into a
pivotal phase 3 study, and (ii) Borrower’s financing plan in form and substance reasonably acceptable to Agent to finance
such pivotal phase 3 study, or (b) Borrower’s receipt, after July 21, 2014, but on or prior to June 30, 2015, of unrestricted
and unencumbered gross cash proceeds in an amount of equal to or greater than Fifty-Five Million Dollars ($55,000,000.00) from
the issuance and sale by Borrower of its equity securities, Subordinated Indebtedness, and/or strategic capital (or any combination
thereof), in each case with Borrower’s existing investors and investors reasonably acceptable to Agent.


 


“Secured Obligations” means Borrower’s
obligations under this Agreement and any Loan Document, including any obligation to pay any amount now owing or later arising.
Notwithstanding the foregoing, the “Secured Obligations” shall not include any of Borrower’s obligations, liabilities
or duties under the Warrant.


 


“Subordinated Indebtedness” means
Indebtedness subordinated to the Secured Obligations in amounts and on terms and conditions satisfactory to Agent in its sole discretion.


 


“Subsidiary” means an entity,
whether corporate, partnership, limited liability company, joint venture or otherwise, in which Borrower owns or controls 50% or
more of the outstanding voting securities, including each entity listed on Schedule 1 hereto.


 


“Term Commitment” means as to
any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to Borrower in a principal amount not to exceed
the amount set forth under the heading “Term Commitment” opposite such Lender’s name on Schedule 1.1.


 


“Term Loan Advance” and “Term
Loan Advances” are each defined in Recital A hereof.


 



    	6



    	 



    




“Term Loan Interest Rate” means
for any day, a floating per annum rate equal to the greater of either (i) ten and forty-five hundredths of one percent (10.45%),
or (ii) the sum of (A) ten and forty-five hundredths of one percent (10.45%), plus (B) the Prime Rate minus four and one half of
one percent (4.50%); provided however, that upon the occurrence of the Second Milestone Event, the “Term Loan Interest Rate”
shall mean for any day, a floating per annum rate equal to the greater of either (i) nine and ninety-five hundredths of one percent
(9.95%), or (ii) the sum of (A) nine and ninety-five hundredths of one percent (9.95%), plus (B) the Prime Rate minus four and
one half of one percent (4.50%). The Term Loan Interest Rate will change from time to time on the day the Prime Rate changes.


 


“Term Loan Maturity Date” means
March 1, 2018.


 


“Trademark License” means any
written agreement granting any right to use any Trademark or Trademark registration, now owned or hereafter acquired by Borrower
or in which Borrower now holds or hereafter acquires any interest.


 


“Trademarks” means all trademarks
(registered, common law or otherwise) and any applications in connection therewith, including registrations, recordings and applications
in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or
any other country or any political subdivision thereof.


 


“UCC” means the Uniform Commercial
Code as the same is, from time to time, in effect in the State of California; provided, that in the event that, by reason of mandatory
provisions of law, any or all of the attachment, perfection or priority of, or remedies with respect to, Agent’s Lien on
any Collateral is governed by the Uniform Commercial Code as the same is, from time to time, in effect in a jurisdiction other
than the State of California, then the term “UCC” shall mean the Uniform Commercial Code as in effect, from time to
time, in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority
or remedies and for purposes of definitions related to such provisions.


 


“Warrant”
means the Warrant Agreement dated as of even date hereof by and between Agent and Borrower.


 


Unless otherwise specified,
all references in this Agreement or any Annex or Schedule hereto to a “Section,” “subsection,” “Exhibit,”
“Annex,” or “Schedule” shall refer to the corresponding Section, subsection, Exhibit, Annex, or Schedule
in or to this Agreement. Unless otherwise specifically provided herein, any accounting term used in this Agreement or the other
Loan Documents shall have the meaning customarily given such term in accordance with GAAP, and all financial computations hereunder
shall be computed in accordance with GAAP, consistently applied. Unless otherwise defined herein or in the other Loan Documents,
terms that are used herein or in the other Loan Documents and defined in the UCC shall have the meanings given to them in the UCC.


 


SECTION
2.            
THE LOAN


 


2.1        
Term Loan.


 


(a)                
Advances. Subject to the terms and conditions of this Agreement, Lender will severally (and not jointly) make in an amount
not to exceed its respective Term Commitment, and Borrower agrees to draw, an initial Term Loan Advance on the Closing Date in
an amount of Three Million Dollars ($3,000,000). During the First Draw Period, Borrower may request one (1) additional Term Loan
Advance in an amount of Three Million Dollars ($3,000,000). During the Second Draw Period, Borrower may request one (1) additional
Term Loan Advance in an amount of Four Million Dollars ($4,000,000). The aggregate outstanding Term Loan Advances shall not exceed
the Maximum Term Loan Amount. Proceeds of any Advance shall be deposited into an account that is subject to a perfected security
interest in favor of Agent perfected by an Account Control Agreement.


 


(b)                
Advance Request. To obtain a Term Loan Advance, Borrower shall complete, sign and deliver to Agent an Advance Request (at
least five (5) Business Days before the Advance Date). Lender shall fund the Term Loan Advance in the manner requested by the Advance
Request provided that each of the conditions precedent to such Term Loan Advance is satisfied as of the requested Advance Date.


 



    	7



    	 



    




(c)                
Interest. The principal balance of each Term Loan Advance shall bear interest thereon from such Advance Date at the Term
Loan Interest Rate based on a year consisting of 360 days, with interest computed daily based on the actual number of days elapsed.
The Term Loan Interest Rate will float and change on the day the Prime Rate changes from time to time.


 


(d)                
Payment. Borrower will pay interest on each Term Loan Advance on the first (1st) Business Day of each month,
beginning the month after the Advance Date. Commencing on the Amortization Date, and continuing on the first (1st) Business
Day of each month thereafter until the Secured Obligations are repaid, Borrower shall repay the aggregate principal balance of
Term Loan Advances that are outstanding on the day immediately preceding the Amortization Date in equal monthly installments of
principal and interest (mortgage style). After any change in the effective rate hereunder, Agent shall recalculate future payments
of principal and interest to fully amortize the outstanding principal amount over the remaining scheduled monthly payments hereunder
prior to the Term Loan Maturity Date. The entire principal balance of the Term Loan Advances and all accrued but unpaid interest
hereunder, and all other Secured Obligations with respect to the Term Loan Advances, shall be due and payable on Term Loan Maturity
Date. For the avoidance of doubt, in the event of any conversion of a portion of any Term Loan Advance pursuant to Section 8.2
below, the remaining monthly payments described in this Section 2.1(d) shall be recalculated by Agent following such conversion
date to reflect (i) the lower outstanding principal of the Term Loan Advance so converted, and (ii) the lower interest payments
resulting from such reduced principal. Borrower shall make all payments under this Agreement without setoff, recoupment or deduction
and regardless of any counterclaim or defense. Lender will initiate debit entries to Borrower’s account as authorized on
the ACH Authorization on each payment date of all periodic obligations payable to Lender under each Term Loan Advance. Once repaid,
a Term Loan Advance or any portion thereof may not be reborrowed.


 


2.2        
Maximum Interest. Notwithstanding any provision in this Agreement or any other Loan Document, it is the parties’
intent not to contract for, charge or receive interest at a rate that is greater than the maximum rate permissible by law that
a court of competent jurisdiction shall deem applicable hereto (which under the laws of the State of California shall be deemed
to be the laws relating to permissible rates of interest on commercial loans) (the “Maximum Rate”). If a court of competent
jurisdiction shall finally determine that Borrower has actually paid to Lender an amount of interest in excess of the amount that
would have been payable if all of the Secured Obligations had at all times borne interest at the Maximum Rate, then such excess
interest actually paid by Borrower shall be applied as follows: first, to the payment of the Secured Obligations consisting of
the outstanding principal amount of the Term Loan Advances; second, after all principal is repaid, to the payment of Lender’s
accrued interest, costs, expenses, professional fees and any other Secured Obligations; and third, after all Secured Obligations
are repaid, the excess (if any) shall be refunded to Borrower.


 


2.3        
Default Interest. In the event any payment is not paid on the scheduled payment date (other than due to an ACH
Failure), an amount equal to five percent (5%) of the past due amount shall be payable on demand. In addition, upon the occurrence
and during the continuation of an Event of Default hereunder, all Secured Obligations, including principal, interest, compounded
interest, and Lender’s fees and expenses set forth in Section 11.11, shall bear interest at a rate per annum equal to the
rate set forth in Section 2.1(c) plus five percent (5%) per annum. In the event any interest is not paid when due hereunder, delinquent
interest shall be added to principal and shall bear interest on interest, compounded at the rate set forth in Section 2.1(c)
or Section 2.4, as applicable.


 


2.4        
Prepayment. At its option upon at least seven (7) Business Days prior notice to Agent, Borrower may prepay all,
or any portion, of the outstanding Advances by paying the entire principal balance or a portion thereof, all accrued and unpaid
interest on the portion prepaid, all unpaid Agent’s and Lender’s fees and expenses accrued to the date of the repayment
(including the End of Term Charge), together with a prepayment charge on the portion prepaid equal to the following percentage
of the Advance amount being prepaid: if such Advance amounts are prepaid in any of the first twelve (12) months following the Closing
Date, three percent (3.00%); after twelve (12) months but prior to twenty four (24) months, two percent (2.00%); and thereafter,
one percent (1.00%) (each, a “Prepayment Charge”). Borrower agrees that the Prepayment Charge is a reasonable calculation
of Lender’s lost profits in view of the difficulties and impracticality of determining actual damages resulting from an early
repayment of the Advances. Upon the occurrence of a Change in Control, Borrower shall prepay the outstanding amount of all principal
and accrued interest through the prepayment date and all unpaid Agent’s and Lender’s fees and expenses accrued to the
date of the repayment (including the End of Term Charge) together with the applicable Prepayment Charge. Notwithstanding the foregoing,
Agent and Lender agree to waive the Prepayment Charge if Agent and Lender agree to refinance and redocument this Agreement (in
its sole and absolute discretion) prior to the Term Loan Maturity Date.


 


2.5        
End of Term Charge. On the earliest to occur of (i) the Term Loan Maturity Date, (ii) the date that Borrower
prepays all of the outstanding Secured Obligations, or (iii) the date that the Secured Obligations become due and payable, Borrower
shall pay Lender the End of Term Charge. Notwithstanding the required payment date of such charge, it shall be deemed earned by
Lender as of the Closing Date.


 



    	8



    	 



    




2.6        
Notes. If so requested by Lender by written notice to Borrower, then Borrower shall execute and deliver to Lender
(and/or, if applicable and if so specified in such notice, to any Person who is an assignee of Lender pursuant to Section 11.13)
(promptly after Borrower’s receipt of such notice) a Note or Notes to evidence Lender’s Loans.


 


2.7        
Pro Rata Treatment. Each payment (including prepayment) on account of any fee and any reduction of the Term Loan
Advances shall be made pro rata according to the Term Commitments of the relevant Lender.


 


SECTION
3.            
SECURITY INTEREST


 


3.1        
As security for the prompt, complete and indefeasible payment when due (whether on the payment dates or otherwise)
of all the Secured Obligations, Borrower grants to Agent a security interest in all of Borrower’s right, title, and interest
in and to the following personal property whether now owned or hereafter acquired (collectively, the “Collateral”):
(a) Receivables; (b) Equipment; (c) Fixtures; (d) General Intangibles (other than Intellectual Property); (e) Inventory; (f) Investment
Property (but excluding thirty-five percent (35%) of the capital stock of any foreign Subsidiary that constitutes a Permitted Investment);
(g) Deposit Accounts; (h) Cash; (i) Goods; and all other tangible and intangible personal property of Borrower whether now or hereafter
owned or existing, leased, consigned by or to, or acquired by, Borrower and wherever located, and any of Borrower’s property
in the possession or under the control of Agent; and, to the extent not otherwise included, all Proceeds of each of the foregoing
and all accessions to, substitutions and replacements for, and rents, profits and products of each of the foregoing; provided,
however, that the Collateral shall include all Accounts and General Intangibles that consist of rights to
payment and proceeds from the sale, licensing or disposition of all or any part, or rights in, the Intellectual Property
(the “Rights to Payment”). Notwithstanding the foregoing, if a judicial authority (including a U.S. Bankruptcy Court)
holds that a security interest in the underlying Intellectual Property is necessary to have a security interest in the Rights to
Payment, then the Collateral shall automatically, and effective as of the date of this Agreement, include the Intellectual Property
to the extent necessary to permit perfection of Agent’s security interest in the Rights to Payment.


 


SECTION
4.            
CONDITIONS PRECEDENT TO LOAN


 


The obligation of Lender
to make the Term Loan Advances hereunder are subject to the satisfaction by Borrower of the following conditions:


 


4.1        
Initial Advance. On or prior to the Closing Date, Borrower shall have delivered to Agent the following:


 


(a)                
executed originals of the Loan Documents, Account Control Agreements, and all other documents and instruments reasonably
required by Agent to effectuate the transactions contemplated hereby or to create and perfect the Liens of Agent with respect to
all Collateral, in all cases in form and substance reasonably acceptable to Agent;


 


(b)                
certified copy of resolutions of Borrower’s Board evidencing approval of the Loan and other transactions evidenced
by the Loan Documents;


 


(c)                
certified copies of the Certificate of Incorporation and the Bylaws, as amended through the Closing Date, of Borrower;


 


(d)                
a certificate of good standing for Borrower from its state of incorporation and similar certificates from all other jurisdictions
in which it does business and where the failure to be qualified would have a Material Adverse Effect;


 


(e)                
payment of the Facility Charge and reimbursement of Agent’s and Lender’s current expenses reimbursable pursuant
to this Agreement, which amounts may be deducted from the initial Advance; and


 


(f)                 
such other documents as Agent may reasonably request.


 



    	9



    	 



    




4.2        
All Advances. On each Advance Date:


 


(a)                
Agent shall have received  an Advance Request for the relevant Advance as required by Section 2.1(b), duly executed
by Borrower’s Chief Executive Officer or Chief Financial Officer.


 


(b)                
The representations and warranties set forth in this Agreement and in Section 5 and in the Warrant shall be true and
correct in all material respects on and as of the Advance Date with the same effect as though made on and as of such date, except
to the extent such representations and warranties expressly relate to an earlier date.


 


(c)                
Borrower shall be in compliance with all the terms and provisions set forth herein and in each other Loan Document on its
part to be observed or performed, and at the time of and immediately after such Advance no Event of Default shall have occurred
and be continuing.


 


(d)                
Each Advance Request shall be deemed to constitute a representation and warranty by Borrower on the relevant Advance Date
as to the matters specified in paragraphs (b) and (c) of this Section 4.2 and as to the matters set forth in the Advance
Request.


 


4.3        
No Default. As of the Closing Date and each Advance Date, (i) no fact or condition exists that would (or would,
with the passage of time, the giving of notice, or both) constitute an Event of Default and (ii) no event that has had or could
reasonably be expected to have a Material Adverse Effect has occurred and is continuing.


 


SECTION
5.            
REPRESENTATIONS AND WARRANTIES OF BORROWER


 


Borrower represents
and warrants that:


 


5.1        
Corporate Status. Borrower is a corporation duly organized, legally existing and in good standing under the laws
of the State of Delaware and is duly qualified as a foreign corporation in all jurisdictions in which the nature of its business
or location of its properties require such qualifications and where the failure to be qualified could reasonably be expected to
have a Material Adverse Effect. Borrower’s present name, former names (if any), locations, place of formation, tax identification
number, organizational identification number and other information are correctly set forth in Exhibit C, as may be updated by Borrower
in a written notice (including any Compliance Certificate) provided to Agent after the Closing Date.


 


5.2        
Collateral. Borrower owns the Collateral and the Intellectual Property, free of all Liens, except for Permitted
Liens. Borrower has the power and authority to grant to Agent a Lien in the Collateral as security for the Secured Obligations.


 


5.3        
Consents. Borrower’s execution, delivery and performance of the Notes(s) (if any), this Agreement and all
other Loan Documents, (i) have been duly authorized by all necessary corporate action of Borrower, (ii) will not result
in the creation or imposition of any Lien upon the Collateral, other than Permitted Liens and the Liens created by this Agreement
and the other Loan Documents, (iii) do not violate any provisions of Borrower’s Certificate or Articles of Incorporation
(as applicable), bylaws, or any, law, regulation, order, injunction, judgment, decree or writ to which Borrower is subject and
(iv) except as described on Schedule 5.3, do not violate any contract or agreement or require the consent or approval of any
other Person which has not already been obtained. The individual or individuals executing the Loan Documents and the Warrant are
duly authorized to do so.


 


5.4        
Material Adverse Effect. No event that has had or could reasonably be expected to have a Material Adverse Effect
has occurred and is continuing. Borrower is not aware of any event likely to occur that is reasonably expected to result in a Material
Adverse Effect.


 


5.5        
Actions Before Governmental Authorities. Except as described on Schedule 5.5, there are no actions, suits or
proceedings at law or in equity or by or before any governmental authority now pending or, to the knowledge of Borrower, threatened
against or affecting Borrower or its property, which if adversely determined against Borrower or its property, would reasonably
be expected to result in liability in excess of One Hundred Fifty Thousand Dollars ($150,000).


 



    	10



    	 



    




5.6        
Laws. Borrower is not in violation of any law, rule or regulation, or in default with respect to any judgment,
writ, injunction or decree of any governmental authority, where such violation or default is reasonably expected to result in a
Material Adverse Effect. Borrower is not in default in any manner under any provision of any agreement or instrument evidencing
Indebtedness, or any other material agreement to which it is a party or by which it is bound.


 


5.7        
Information Correct and Current. No information, report, Advance Request, financial statement, exhibit or schedule
furnished, by or on behalf of Borrower to Agent in connection with any Loan Document or included therein or delivered pursuant
thereto contained, contains or will contain any material misstatement of fact or omitted, omits or will omit to state any material
fact necessary to make the statements therein, in the light of the circumstances under which they were, are or will be made, not
misleading at the time such statement was made or deemed made. Additionally, any and all financial or business projections provided
by Borrower to Agent, whether prior to or after the Closing Date, shall be (i) provided in good faith and based on the most current
data and information available to Borrower, and (ii) the most current of such projections provided to Borrower’s Board.


 


5.8        
Tax Matters. Except as described on Schedule 5.8, (a) Borrower has filed all federal, state and local tax returns
that it is required to file except with respect to taxes that do not exceed Fifty Thousand Dollars ($50,000) in the aggregate,
(b) Borrower has duly paid or fully reserved for all taxes or installments thereof (including any interest or penalties) as and
when due, which have or may become due pursuant to such returns, except with respect to taxes that do not exceed Fifty Thousand
Dollars ($50,000) in the aggregate, and (c) Borrower has paid or fully reserved for any tax assessment received by Borrower for
the three (3) years preceding the Closing Date, if any (including any taxes being contested in good faith and by appropriate proceedings).


 


5.9        
Intellectual Property Claims. Borrower is the sole owner of, or otherwise has the right to use, the Intellectual
Property. Except as described on Schedule 5.9, (i) each of the material Copyrights, Trademarks and Patents is valid and enforceable,
(ii) no material part of the Intellectual Property has been judged invalid or unenforceable, in whole or in part, and (iii) no
claim has been made to Borrower that any material part of the Intellectual Property violates the rights of any third party. Exhibit D
is a true, correct and complete list of each of Borrower’s Patents, registered Trademarks, registered Copyrights, and material
agreements under which Borrower licenses Intellectual Property from third parties (other than shrink-wrap software licenses), together
with application or registration numbers, as applicable, owned by Borrower or any Subsidiary, in each case as of the Closing Date.
Borrower is not in material breach of, nor has Borrower failed to perform any material obligations under, any of the foregoing
contracts, licenses or agreements and, to Borrower’s knowledge, no third party to any such contract, license or agreement
is in material breach thereof or has failed to perform any material obligations thereunder.


 


5.10      
Intellectual Property. Except as described on Schedule 5.10, Borrower has, or in the case of any proposed business,
will have, all material rights with respect to Intellectual Property necessary in the operation or conduct of Borrower’s
business as currently conducted and proposed to be conducted by Borrower. Without limiting the generality of the foregoing, and
in the case of Licenses, except for restrictions that are unenforceable under Division 9 of the UCC, Borrower has the right, to
the extent required to operate Borrower’s business, to freely transfer, license or assign Intellectual Property without condition,
restriction or payment of any kind (other than license payments in the ordinary course of business) to any third party, and Borrower
owns or has the right to use, pursuant to valid licenses, all software development tools, library functions, compilers and all
other third-party software and other items that are used in the design, development, promotion, sale, license, manufacture, import,
export, use or distribution of Borrower Products.


 


5.11      
Borrower Products. Except as described on Schedule 5.11, no Intellectual Property owned by Borrower or Borrower
Product has been or is subject to any actual or, to the knowledge of Borrower, threatened litigation, proceeding (including any
proceeding in the United States Patent and Trademark Office or any corresponding foreign office or agency) or outstanding decree,
order, judgment, settlement agreement or stipulation that restricts in any manner Borrower’s use, transfer or licensing thereof
or that may affect the validity, use or enforceability thereof. There is no decree, order, judgment, agreement, stipulation, arbitral
award or other provision entered into in connection with any litigation or proceeding that obligates Borrower to grant licenses
or ownership interest in any future Intellectual Property related to the operation or conduct of the business of Borrower or Borrower
Products. Borrower has not received any written notice or claim, or, to the knowledge of Borrower, oral notice or claim, challenging
or questioning Borrower’s ownership in any Intellectual Property (or written notice of any claim challenging or questioning
the ownership in any licensed Intellectual Property of the owner thereof) or suggesting that any third party has any claim of legal
or beneficial ownership with respect thereto nor, to Borrower’s knowledge, is there a reasonable basis for any such claim.
Neither Borrower’s use of its Intellectual Property nor the production and sale of Borrower Products infringes the Intellectual
Property or other rights of others.


 



    	11



    	 



    




5.12      
Financial Accounts. Exhibit E, as may be updated by Borrower in a written notice provided to Agent after the
Closing Date, is a true, correct and complete list of (a) all banks and other financial institutions at which Borrower or
any Subsidiary maintains Deposit Accounts and (b) all institutions at which Borrower or any Subsidiary maintains an account holding
Investment Property, and such exhibit correctly identifies the name, address and telephone number of each bank or other institution,
the name in which the account is held, a description of the purpose of the account, and the complete account number therefor.


 


5.13      
Employee Loans. Borrower has no outstanding loans to any employee, officer or director of Borrower nor has Borrower
guaranteed the payment of any loan made to an employee, officer or director of Borrower by a third party.


 


5.14      
Capitalization and Subsidiaries. Borrower’s capitalization as of the Closing Date is set forth on Schedule
5.14 annexed hereto. Borrower does not own any stock, partnership interest or other securities of any Person, except for Permitted
Investments. Attached as Schedule 5.14, as may be updated by Borrower in a written notice provided after the Closing Date, is a
true, correct and complete list of each Subsidiary.


 


SECTION
6.            
INSURANCE; INDEMNIFICATION


 


6.1        
Coverage. Borrower shall cause to be carried and maintained commercial general liability insurance, on an occurrence
form, against risks customarily insured against in Borrower’s line of business. Such risks shall include the risks of bodily
injury, including death, property damage, personal injury, advertising injury, and contractual liability per the terms of the indemnification
agreement found in Section 6.3. Borrower must maintain a minimum of $2,000,000 of commercial general liability insurance for
each occurrence. Borrower has and agrees to maintain a minimum of $2,000,000 of directors’ and officers’ insurance
for each occurrence and $5,000,000 in the aggregate. So long as there are any Secured Obligations outstanding, Borrower shall also
cause to be carried and maintained insurance upon the Collateral, insuring against all risks of physical loss or damage howsoever
caused, in an amount not less than the full replacement cost of the Collateral, provided that such insurance may be subject to
standard exceptions and deductibles.


 


6.2        
Certificates. Borrower shall deliver to Agent certificates of insurance that evidence Borrower’s compliance
with its insurance obligations in Section 6.1 and the obligations contained in this Section 6.2. Borrower’s insurance
certificate shall state Agent is an additional insured for commercial general liability, a loss payee for all risk property damage
insurance, subject to the insurer’s approval, and a loss payee for property insurance and additional insured for liability
insurance for any future insurance that Borrower may acquire from such insurer. Attached to the certificates of insurance will
be additional insured endorsements for liability and lender’s loss payable endorsements for all risk property damage insurance.
Notwithstanding the foregoing, (a) so long as no Event of Default has occurred and is continuing, Borrower shall have the option
of applying the proceeds of any casualty policy up to Five Hundred Thousand Dollars ($500,000) in the aggregate for all losses
under all casualty policies in any one year, toward the replacement or repair of destroyed or damaged property; provided that any
such replaced or repaired property (i) shall be of equal or like value as the replaced or repaired Collateral and (ii) shall be
deemed Collateral in which Agent has been granted a first priority security interest, and (b) after the occurrence and during the
continuance of an Event of Default, all proceeds payable under such casualty policy shall, at the option of Agent or Lender, be
payable to Lender on account of the Obligations. All certificates of insurance will provide for a minimum of thirty (30) days advance
written notice to Agent of cancellation or any other change adverse to Agent’s interests. Any failure of Agent to scrutinize
such insurance certificates for compliance is not a waiver of any of Agent’s rights, all of which are reserved.


 


6.3        
Indemnity. Borrower agrees to indemnify and hold Agent, Lender and their officers, directors, employees, agents,
in-house attorneys, representatives and shareholders (each, an “Indemnified Person”) harmless from and against any
and all claims, costs, expenses, damages and liabilities (including such claims, costs, expenses, damages and liabilities based
on liability in tort, including strict liability in tort), including reasonable attorneys’ fees and disbursements and other
costs of investigation or defense (including those incurred upon any appeal) (collectively, “Liabilities”), that may
be instituted or asserted against or incurred by such Indemnified Person as the result of credit having been extended, suspended
or terminated under this Agreement and the other Loan Documents or the administration of such credit, or in connection with or
arising out of the transactions contemplated hereunder and thereunder, or any actions or failures to act in connection therewith,
or arising out of the disposition or utilization of the Collateral, excluding in all cases Liabilities to the extent resulting
solely from any Indemnified Person’s gross negligence or willful misconduct. Borrower agrees to pay, and to save Agent and
Lender harmless from, any and all liabilities with respect to, or resulting from any delay in paying, any and all excise, sales
or other similar taxes (excluding taxes imposed on or measured by the net income of Agent or Lender) that may be payable or determined
to be payable with respect to any of the Collateral or this Agreement. In no event shall any Indemnified Person be liable on any
theory of liability for any special, indirect, consequential or punitive damages (including any loss of profits, business or anticipated
savings).


 



    	12



    	 



    




SECTION
7.            
COVENANTS OF BORROWER


 


Borrower agrees as
follows:


 


7.1        
Financial Reports. Borrower shall furnish to Agent the financial statements and reports listed hereinafter (the
“Financial Statements”):


 


(a)                
as soon as practicable (and in any event within 30 days) after the end of each month, unaudited interim and year-to-date
financial statements as of the end of such month (prepared on a consolidated and consolidating basis, if applicable), including
balance sheet and related statements of income and cash flows accompanied by a report detailing any material contingencies (including
the commencement of any material litigation by or against Borrower) or any other occurrence that would reasonably be expected to
have a Material Adverse Effect, all certified by Borrower’s Chief Executive Officer or Chief Financial Officer to the effect
that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, (ii) that they are subject to normal
year end adjustments, and (iii) they do not contain certain non-cash items that are customarily included in quarterly and annual
financial statements;


 


(b)                
as soon as practicable (and in any event within 40 days) after the end of each calendar quarter, unaudited interim and year-to-date
financial statements as of the end of such calendar quarter (prepared on a consolidated and consolidating basis, if applicable),
including balance sheet and related statements of income and cash flows accompanied by a report detailing any material contingencies
(including the commencement of any material litigation by or against Borrower) or any other occurrence that would reasonably be
expected to have a Material Adverse Effect, certified by Borrower’s Chief Executive Officer or Chief Financial Officer to
the effect that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, and (ii) that they are
subject to normal year end adjustments; as well as the most recent capitalization table for Borrower;


 


(c)                
as soon as practicable (and in any event within one hundred fifty (150) days) after the end of each fiscal year, unqualified
(other than for Borrower’s fiscal year ending December 31, 2014, a “going concern” opinion qualification relating
solely to the insufficient cash of Borrower to cover operational requirements for the next twelve (12) month period) audited financial
statements as of the end of such year (prepared on a consolidated and consolidating basis, if applicable), including balance sheet
and related statements of income and cash flows, and setting forth in comparative form the corresponding figures for the preceding
fiscal year, certified by a firm of independent certified public accountants selected by Borrower and reasonably acceptable to
Agent, accompanied by any management report from such accountants;


 


(d)                
 as soon as practicable (and in any event within 30 days) after the end of each month, a Compliance Certificate in the form
of Exhibit F;


 


(e)                
promptly after the sending or filing thereof, as the case may be, copies of any proxy statements, financial statements or
reports that Borrower has made available to holders of its capital stock and copies of any regular, periodic and special reports
or registration statements that Borrower files with the Securities and Exchange Commission or any governmental authority that may
be substituted therefor, or any national securities exchange;


 


(f)                 
prior to the occurrence of an Initial Public Offering, at the same time and in the same manner as it gives to its directors,
copies of all notices, minutes, consents and other materials (other than materials that (i) present a potential conflict of interest
with Lender, (ii) relate to executive sessions, (iii) are covered by attorney-client privilege, (iv) that relate to confidential
compensation information, or (v) are subject to confidentiality agreements) that Borrower provides to its directors in connection
with meetings of the Board, and as soon as practical after Board approval, copies of the minutes of such meeting; and


 


(g)                
financial and business projections promptly following their approval by Borrower’s Board, and in any event, within
30 days following approval by the Board of the budget of Borrower, but at least annually, as well as budgets, operating plans and
other financial information reasonably requested by Agent.


 



    	13



    	 



    




(h)                
Notwithstanding anything to the contrary in this Section 7.1, upon completion of the Borrower’s Initial Public Offering,
documents required to be delivered pursuant to the terms hereof (to the extent any such documents are included in materials otherwise
filed with the Securities and Exchange Commission) may be delivered electronically and if so delivered, shall be deemed to have
been delivered on the date on which Borrower posts such documents, or provides a link thereto, on Borrower’s website on the
Internet at Borrower’s website address; provided, however, Borrower shall promptly notify Agent and Lender in writing (which
may be by electronic mail) of the posting of any such documents.


 


Borrower shall not make any change
in its (a) accounting policies or reporting practices or (b) fiscal years or fiscal quarters. The fiscal year of Borrower shall
end on December 31.


 


The executed Compliance Certificate
may be sent via facsimile to Agent at (650) 473-9194 or via e-mail to BJadot@herculestech.com. All Financial Statements required
to be delivered pursuant to clauses (a), (b) and (c) shall be sent via e-mail to financialstatements@herculestech.com with a copy
to BJadot@herculestech.com and BBang@herculestech.com provided, that if e-mail is not available or sending such
Financial Statements via e-mail is not possible, they shall be sent via facsimile to Agent at: (866) 468-8916, attention Chief
Credit Officer.


 


7.2        
Management Rights. Borrower shall permit any representative that Agent or Lender authorizes, including its attorneys
and accountants, to inspect the Collateral and examine and make copies and abstracts of the books of account and records of Borrower
at reasonable times and upon reasonable notice during normal business hours. In addition, any such representative shall have the
right to meet with management and officers of Borrower to discuss such books of account and records. In addition, Agent or Lender
shall be entitled at reasonable times and intervals to consult with and advise the management and officers of Borrower concerning
significant business issues affecting Borrower. Such consultations shall not unreasonably interfere with Borrower’s business
operations. The parties intend that the rights granted Agent and Lender shall constitute “management rights” within
the meaning of 29 C.F.R Section 2510.3-101(d)(3)(ii), but that any advice, recommendations or participation by Agent or Lender
with respect to any business issues shall not be deemed to give Agent or Lender, nor be deemed an exercise by Agent or Lender of,
control over Borrower’s management or policies.


 


7.3        
Further Assurances. Borrower shall from time to time execute, deliver and file, alone or with Agent, any financing
statements, security agreements, collateral assignments, notices, control agreements, or other documents to perfect or give the
highest priority to Agent’s Lien on the Collateral. Borrower shall from time to time procure any instruments or documents
as may be requested by Agent, and take all further action that may be necessary or desirable, or that Agent may reasonably request,
to perfect and protect the Liens granted hereby and thereby. In addition, and for such purposes only, Borrower hereby authorizes
Agent to execute and deliver on behalf of Borrower and to file such financing statements, collateral assignments, notices, control
agreements, security agreements and other documents without the signature of Borrower either in Agent’s name or in the name
of Agent as agent and attorney-in-fact for Borrower. Borrower shall protect and defend Borrower’s title to the Collateral
and Agent’s Lien thereon against all Persons claiming any interest adverse to Borrower or Agent other than Permitted Liens.


 


7.4        
Indebtedness. Borrower shall not create, incur, assume, guarantee or be or remain liable with respect to any
Indebtedness, or permit any Subsidiary so to do, other than Permitted Indebtedness, or prepay any Indebtedness or take any actions
which impose on Borrower an obligation to prepay any Indebtedness, except for the conversion of Indebtedness into equity securities
and the payment of cash in lieu of fractional shares in connection with such conversion.


 


7.5        
Collateral. Borrower shall at all times keep the Collateral, the Intellectual Property and all other property
and assets used in Borrower’s business or in which Borrower now or hereafter holds any interest free and clear from any Liens
whatsoever (except for Permitted Liens), and shall give Agent prompt written notice of any legal process affecting the Collateral,
the Intellectual Property, such other property and assets, or any Liens thereon, provided however, that the Collateral and such
other property and assets may be subject to Permitted Liens except that there shall be no Liens whatsoever on Intellectual Property.
Borrower shall cause its Subsidiaries to protect and defend such Subsidiary’s title to its assets from and against all Persons
claiming any interest adverse to such Subsidiary, and Borrower shall cause its Subsidiaries at all times to keep such Subsidiary’s
property and assets free and clear from any Liens whatsoever (except for Permitted Liens, provided however, that there shall be
no Liens whatsoever on Intellectual Property), and shall give Agent prompt written notice of any legal process affecting such Subsidiary’s
assets. Borrower shall not agree with any Person other than Agent or Lender not to encumber its property.


 



    	14



    	 



    




7.6        
Investments. Borrower shall not directly or indirectly acquire or own, or make any Investment in or to any Person,
or permit any of its Subsidiaries so to do, other than Permitted Investments.


 


7.7        
Distributions. Borrower shall not, and shall not allow any Subsidiary to, (a) repurchase or redeem any class
of stock or other equity interest other than pursuant to employee, director or consultant repurchase plans or other similar agreements,
provided, however, in each case the repurchase or redemption price does not exceed the original consideration paid for such stock
or equity interest, or (b) declare or pay any cash dividend or make a cash distribution on any class of stock or other equity interest,
except that a Subsidiary may pay dividends or make distributions to Borrower, or (c) lend money to any employees, officers or directors
or guarantee the payment of any such loans granted by a third party in excess of $100,000 in the aggregate or (d) waive, release
or forgive any Indebtedness owed by any employees, officers or directors in excess of $100,000 in the aggregate.


 


7.8        
Transfers. Except for Permitted Transfers, Borrower shall not voluntarily or involuntarily transfer, sell, lease,
license, lend or in any other manner convey any equitable, beneficial or legal interest in any material portion of its assets.


 


7.9        
Mergers or Acquisitions. Without the Agent’s prior written consent, which consent shall not be unreasonably
withheld, Borrower shall not merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with or into any
other business organization (other than mergers or consolidations of (a) a Subsidiary which is not a Borrower into another Subsidiary
or into Borrower or (b) a Borrower into another Borrower), or acquire, or permit any of its Subsidiaries to acquire, all or substantially
all of the capital stock or property of another Person.


 


7.10      
Taxes. Borrower and its Subsidiaries shall pay when due all taxes, fees or other charges of any nature whatsoever
(together with any related interest or penalties) now or hereafter imposed or assessed against Borrower, Agent, Lender or the Collateral
or upon Borrower’s ownership, possession, use, operation or disposition thereof or upon Borrower’s rents, receipts
or earnings arising therefrom (other than taxes imposed on or measured by the net income of Agent or Lender). Borrower shall file
on or before the due date therefor all personal property tax returns in respect of the Collateral. Notwithstanding the foregoing,
Borrower may contest, in good faith and by appropriate proceedings, taxes for which Borrower maintains adequate reserves therefor
in accordance with GAAP.


 


7.11      
Corporate Changes. Neither Borrower nor any Subsidiary shall change its corporate name, legal form or jurisdiction
of formation without twenty (20) days’ prior written notice to Agent. Neither Borrower nor any Subsidiary shall suffer a
Change in Control. Neither Borrower nor any Subsidiary shall relocate its chief executive office or its principal place of business
unless: (i) it has provided prior written notice to Agent; and (ii) such relocation shall be within the continental United States.
Neither Borrower nor any Subsidiary shall relocate any item of Collateral (other than (x) sales of Inventory in the ordinary course
of business, (y) relocations of Equipment having an aggregate value of up to $150,000 in any fiscal year, and (z) relocations of
Collateral from a location described on Exhibit C to another location described on Exhibit C) unless (i) it has provided prompt
written notice to Agent, (ii) such relocation is within the continental United States and, (iii) if such relocation is to a third
party bailee, it has delivered a bailee agreement in form and substance reasonably acceptable to Agent.


 


7.12      
Deposit Accounts. Neither Borrower nor any Subsidiary shall maintain any Deposit Accounts (other than Deposit
Accounts exclusively used for payroll, payroll taxes and other employee wage and benefit payments to or for the benefit of Borrower’s
employees and identified to Agent by Borrower as such), or accounts holding Investment Property, except with respect to which Agent
has an Account Control Agreement.


 


7.13      
Subsidiaries. Borrower shall notify Agent of each Subsidiary formed subsequent to the Closing Date and, within
15 days of formation, shall cause any such Subsidiary to execute and deliver to Agent a Joinder Agreement.


 


7.14      
Notification of Event of Default. Borrower shall notify Agent immediately of the occurrence of any Event of Default,
such notice to be sent via facsimile to Agent.


 



    	15



    	 



    




SECTION
8.            
RIGHT TO invest; RIGHT TO CONVERT


 


8.1        
Lender or its assignee or nominee shall have the right, in its discretion, to participate in a Subsequent Financing
(as defined in the Equity Rights Letter Agreement) pursuant to the terms set forth in the Equity Rights Letter Agreement.


 


8.2        
Lender shall have the right, in its discretion, to convert a portion of the Loan in a Subsequent Financing (as
defined in the Equity Rights Letter Agreement) pursuant to the terms set forth in the Equity Rights Letter Agreement.


 


SECTION
9.            
EVENTS OF DEFAULT


 


The occurrence of any
one or more of the following events shall be an Event of Default:


 


9.1        
Payments. Borrower fails to pay any amount due under this Agreement, the Notes, or any of the other Loan Documents
on the due date (or within three (3) Business Days of the due date, provided that such late payment is due to an ACH Failure);
or


 


9.2        
Covenants. Borrower breaches or defaults in the performance of any covenant or Secured Obligation under this
Agreement, or any of the other Loan Documents or any other agreement among Borrower, Agent and Lender, and (a) with respect
to a default under any covenant under this Agreement (other than under Sections 6, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, and 7.14), any
other Loan Document or any other agreement among Borrower, Agent and Lender, such default continues for more than ten (10) days
after the earlier of the date on which (i) Agent or Lender has given notice of such default to Borrower and (ii) Borrower has actual
knowledge of such default or (b) with respect to a default under any of Sections 6, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, and 7.14, the
occurrence of such default; or


 


9.3        
Material Adverse Effect. A circumstance has occurred that would reasonably be expected to have a Material Adverse
Effect; or


 


9.4        
Representations. Any representation or warranty made by Borrower in any Loan Document or in the Warrant shall
have been false or misleading in any material respect; or


 


9.5        
Insolvency. Borrower (A) (i) shall make an assignment for the benefit of creditors; or (ii) shall be
unable to pay its debts as they become due, or be unable to pay or perform under the Loan Documents, or shall become insolvent;
or (iii) shall file a voluntary petition in bankruptcy; or (iv) shall file any petition, answer, or document seeking
for itself any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present
or future statute, law or regulation pertinent to such circumstances; or (v) shall seek or consent to or acquiesce in the
appointment of any trustee, receiver, or liquidator of Borrower or of all or any substantial part (i.e., 33-1/3% or more) of the
assets or property of Borrower; or (vi) shall cease operations of its business as its business has normally been conducted,
or terminate substantially all of its employees; or (vii) Borrower or its directors or majority shareholders shall take any
action initiating any of the foregoing actions described in clauses (i) through (vi); or (B) either (i) forty-five (45)
days shall have expired after the commencement of an involuntary action against Borrower seeking reorganization, arrangement, composition,
readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation, without such action
being dismissed or all orders or proceedings thereunder affecting the operations or the business of Borrower being stayed; or (ii) a
stay of any such order or proceedings shall thereafter be set aside and the action setting it aside shall not be timely appealed;
or (iii) Borrower shall file any answer admitting or not contesting the material allegations of a petition filed against Borrower
in any such proceedings; or (iv) the court in which such proceedings are pending shall enter a decree or order granting the
relief sought in any such proceedings; or (v) forty-five (45) days shall have expired after the appointment, without the consent
or acquiescence of Borrower, of any trustee, receiver or liquidator of Borrower or of all or any substantial part of the properties
of Borrower without such appointment being vacated; or


 


9.6        
Attachments; Judgments. Any portion of Borrower’s assets is attached or seized, or a levy is filed against
any such assets, or a judgment or judgments is/are entered for the payment of money, individually or in the aggregate, of at least
$100,000, or Borrower is enjoined or in any way prevented by court order from conducting any part of its business; or


 



    	16



    	 



    




9.7        
Other Obligations. The occurrence of any default (beyond any applicable grace, appeal or cure period, if any)
under any agreement or obligation of Borrower involving any Indebtedness in excess of $100,000, or the occurrence of any default
under any agreement or obligation of Borrower that could reasonably be expected to have a Material Adverse Effect.


 


SECTION
10.         REMEDIES


 


10.1      
General. Upon and during the continuance of any one or more Events of Default, (i) Agent may, at its option,
accelerate and demand payment of all or any part of the Secured Obligations together with a Prepayment Charge and declare them
to be immediately due and payable (provided, that upon the occurrence of an Event of Default of the type described in Section 9.5,
all of the Secured Obligations shall automatically be accelerated and made due and payable, in each case without any further notice
or act), (ii) Agent may, at its option, sign and file in Borrower’s name any and all collateral assignments, notices, control
agreements, security agreements and other documents it deems necessary or appropriate to perfect or protect the repayment of the
Secured Obligations, and in furtherance thereof, Borrower hereby grants Agent an irrevocable power of attorney coupled with an
interest, and (iii) Agent may notify any of Borrower’s account debtors to make payment directly to Agent, compromise the
amount of any such account on Borrower’s behalf and endorse Agent’s name without recourse on any such payment for deposit
directly to Agent’s account. Agent may exercise all rights and remedies with respect to the Collateral under the Loan Documents
or otherwise available to it under the UCC and other applicable law, including the right to release, hold, sell, lease, liquidate,
collect, realize upon, or otherwise dispose of all or any part of the Collateral and the right to occupy, utilize, process and
commingle the Collateral. All Agent’s rights and remedies shall be cumulative and not exclusive.


 


10.2      
Collection; Foreclosure. Upon the occurrence and during the continuance of any Event of Default, Agent may, at
any time or from time to time, apply, collect, liquidate, sell in one or more sales, lease or otherwise dispose of, any or all
of the Collateral, in its then condition or following any commercially reasonable preparation or processing, in such order as Agent
may elect. Any such sale may be made either at public or private sale at its place of business or elsewhere. Borrower agrees that
any such public or private sale may occur upon ten (10) calendar days’ prior written notice to Borrower. Agent may require
Borrower to assemble the Collateral and make it available to Agent at a place designated by Agent that is reasonably convenient
to Agent and Borrower. The proceeds of any sale, disposition or other realization upon all or any part of the Collateral shall
be applied by Agent in the following order of priorities:


 


First, to Agent and Lender in an
amount sufficient to pay in full Agent’s and Lender’s costs and professionals’ and advisors’ fees and expenses
as described in Section 11.11;


 


Second, to Lender in an amount equal
to the then unpaid amount of the Secured Obligations (including principal, interest, and the Default Rate interest), in such order
and priority as Agent may choose in its sole discretion; and


 


Finally, after the full, final,
and indefeasible payment in Cash of all of the Secured Obligations, to any creditor holding a junior Lien on the Collateral, or
to Borrower or its representatives or as a court of competent jurisdiction may direct.


 


Agent shall be deemed to have acted reasonably in the custody,
preservation and disposition of any of the Collateral if it complies with the obligations of a secured party under the UCC.


 


10.3      
No Waiver. Agent shall be under no obligation to marshal any of the Collateral for the benefit of Borrower or
any other Person, and Borrower expressly waives all rights, if any, to require Agent to marshal any Collateral.


 


10.4      
Cumulative Remedies. The rights, powers and remedies of Agent hereunder shall be in addition to all rights, powers
and remedies given by statute or rule of law and are cumulative. The exercise of any one or more of the rights, powers and remedies
provided herein shall not be construed as a waiver of or election of remedies with respect to any other rights, powers and remedies
of Agent.


 



    	17



    	 



    




SECTION
11.         MISCELLANEOUS


 


11.1      
Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be
effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law,
such provision shall be ineffective only to the extent and duration of such prohibition or invalidity, without invalidating the
remainder of such provision or the remaining provisions of this Agreement.


 


11.2      
Notice. Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service
of process or other communication (including the delivery of Financial Statements) that is required, contemplated, or permitted
under the Loan Documents or with respect to the subject matter hereof shall be in writing (which shall include email transmissions)
and shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (i) the day of transmission
by facsimile, email or hand delivery or delivery by an overnight express service or overnight mail delivery service; or (ii) the
third calendar day after deposit in the United States mails, with proper first class postage prepaid, in each case addressed to
the party to be notified as follows:


 


If to Agent:                       HERCULES
TECHNOLOGY GROWTH CAPITAL, INC.

Legal Department

Attention: Chief Legal Officer and Mr. Bryan Jadot

400 Hamilton Avenue, Suite 310

Palo Alto, California 94301

Facsimile: 650-473-9194

Telephone: 650-289-3060 

Email: bbang@herculestech.com and bjadot@herculestech.com


 


If to Borrower:                  EDGE THERAPEUTICS,
INC.

Attention: Andrew Einhorn

200 Connell Drive, Suite 1600

Berkeley Heights, New Jersey 07922

Facsimile: 908-790-1212

Telephone: 800-208-3343 

Email: aeinhorn@edgetherapeutics.com


 


or to such other address as each
party may designate for itself by like notice.


 


11.3      
Entire Agreement; Amendments.


 


(a)                
This Agreement and the other Loan Documents constitute the entire agreement and understanding of the parties hereto in respect
of the subject matter hereof and thereof, and supersede and replace in their entirety any prior proposals, term sheets, non-disclosure
or confidentiality agreements, letters, negotiations or other documents or agreements, whether written or oral, with respect to
the subject matter hereof or thereof (including Agent’s revised proposal letter dated July 21, 2014).


 



    	18



    	 



    




(b)                
Neither this Agreement, any other Loan Document, nor any terms hereof or thereof may be amended, supplemented or modified
except in accordance with the provisions of this Section 11.3(b). The Required Lenders and Borrower party to the relevant Loan
Document may, or, with the written consent of the Required Lenders, Agent and Borrower party to the relevant Loan Document may,
from time to time, (i) enter into written amendments, supplements or modifications hereto and to the other Loan Documents for the
purpose of adding any provisions to this Agreement or the other Loan Documents or changing in any manner the rights of Lenders
or of Borrower hereunder or thereunder or (ii) waive, on such terms and conditions as the Required Lenders or Agent, as the case
may be, may specify in such instrument, any of the requirements of this Agreement or the other Loan Documents or any default or
Event of Default and its consequences; provided, however, that no such waiver and no such amendment, supplement or modification
shall (A) forgive the principal amount or extend the final scheduled date of maturity of any Loan, extend the scheduled date of
any amortization payment in respect of any Term Loan, reduce the stated rate of any interest or fee payable hereunder, or extend
the scheduled date of any payment thereof, in each case without the written consent of each Lender directly affected thereby; (B)
eliminate or reduce the voting rights of any Lender under this Section 11.3(b) without the written consent of such Lender; (C)
reduce any percentage specified in the definition of Required Lenders, consent to the assignment or transfer by Borrower of any
of its rights and obligations under this Agreement and the other Loan Documents, release all or substantially all of the Collateral
or release a Borrower from its obligations under the Loan Documents, in each case without the written consent of all Lenders; or
(D) amend, modify or waive any provision of Section 11.17 without the written consent of Agent. Any such waiver and any such amendment,
supplement or modification shall apply equally to each Lender and shall be binding upon Borrower, Lender, Agent and all future
holders of the Loans.


 


11.4      
No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this
Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted
jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of
the authorship of any provisions of this Agreement.


 


11.5      
No Waiver. The powers conferred upon Agent and Lender by this Agreement are solely to protect its rights hereunder
and under the other Loan Documents and its interest in the Collateral and shall not impose any duty upon Agent or Lender to exercise
any such powers. No omission or delay by Agent or Lender at any time to enforce any right or remedy reserved to it, or to require
performance of any of the terms, covenants or provisions hereof by Borrower at any time designated, shall be a waiver of any such
right or remedy to which Agent or Lender is entitled, nor shall it in any way affect the right of Agent or Lender to enforce such
provisions thereafter.


 


11.6      
Survival. All agreements, representations and warranties contained in this Agreement and the other Loan Documents
or in any document delivered pursuant hereto or thereto shall be for the benefit of Agent and Lender and shall survive the execution
and delivery of this Agreement and the expiration or other termination of this Agreement.


 


11.7      
Successors and Assigns. The provisions of this Agreement and the other Loan Documents shall inure to the benefit
of and be binding on Borrower and its permitted assigns (if any). Borrower shall not assign its obligations under this Agreement
or any of the other Loan Documents without Agent’s express prior written consent, and any such attempted assignment shall
be void and of no effect. Agent and Lender may assign, transfer, or endorse its rights hereunder and under the other Loan Documents
without prior notice to Borrower, and all of such rights shall inure to the benefit of Agent’s and Lender’s successors
and assigns. Notwithstanding the foregoing, so long as no Event of Default has occurred and is continuing, Agent and Lender shall
not assign any interest in the Loan Document to an operating company which is a direct competitor of Borrower.


 


11.8      
Governing Law. This Agreement and the other Loan Documents have been negotiated and delivered to Agent and Lender
in the State of New York, and shall have been accepted by Agent and Lender in the State of New York. Payment to Agent and Lender
by Borrower of the Secured Obligations is due in the State of New York. This Agreement and the other Loan Documents shall be governed
by, and construed and enforced in accordance with, the laws of the State of New York, excluding conflict of laws principles that
would cause the application of laws of any other jurisdiction.


 



    	19



    	 



    




11.9      
Consent to Jurisdiction and Venue. All judicial proceedings (to the extent that the reference requirement of
Section 11.10 is not applicable) arising in or under or related to this Agreement or any of the other Loan Documents may be brought
in any state or federal court located in the State of New York. By execution and delivery of this Agreement, each party hereto
generally and unconditionally: (a) consents to nonexclusive personal jurisdiction in New York County, State of New York; (b) waives
any objection as to jurisdiction or venue in New York County, State of New York; (c) agrees not to assert any defense based
on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered
thereby in connection with this Agreement or the other Loan Documents. Service of process on any party hereto in any action arising
out of or relating to this Agreement shall be effective if given in accordance with the requirements for notice set forth in Section 11.2,
and shall be deemed effective and received as set forth in Section 11.2. Nothing herein shall affect the right to serve process
in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction.


 


11.10    
Mutual Waiver of Jury Trial / Judicial Reference. Because disputes arising in connection with complex financial
transactions are most quickly and economically resolved by an experienced and expert Person and the parties wish applicable state
and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved by a judge applying
such applicable laws. EACH OF BORROWER, AGENT AND LENDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE
OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED
BY BORROWER AGAINST AGENT, LENDER OR THEIR RESPECTIVE ASSIGNEE OR BY AGENT, LENDER OR THEIR RESPECTIVE ASSIGNEE AGAINST BORROWER.
This waiver extends to all such Claims, including Claims that involve Persons other than Agent, Borrower and Lender; Claims that
arise out of or are in any way connected to the relationship among Borrower, Agent and Lender; and any Claims for damages, breach
of contract, tort, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement, any other
Loan Document.


 


11.11    
Professional Fees. Borrower promises to pay Agent’s and Lender’s documented fees and expenses necessary
to finalize the loan documentation, including but not limited to reasonable documented attorneys fees, UCC searches, filing costs,
and other miscellaneous expenses. In addition, Borrower promises to pay any and all reasonable documented attorneys’ and
other professionals’ fees and expenses (including reasonable fees and expenses of in-house counsel) incurred by Agent and
Lender after the Closing Date in connection with or related to: (a) the Loan; (b) the administration, collection, or
enforcement of the Loan; (c) the amendment or modification of the Loan Documents; (d) any waiver, consent, release, or
termination under the Loan Documents; (e) the protection, preservation, audit, field exam, sale, lease, liquidation, or disposition
of Collateral or the exercise of remedies with respect to the Collateral; (f) any legal, litigation, administrative, arbitration,
or out of court proceeding in connection with or related to Borrower or the Collateral, and any appeal or review thereof; and (g) any
bankruptcy, restructuring, reorganization, assignment for the benefit of creditors, workout, foreclosure, or other action related
to Borrower, the Collateral, the Loan Documents, including representing Agent or Lender in any adversary proceeding or contested
matter commenced or continued by or on behalf of Borrower’s estate, and any appeal or review thereof.


 



    	20



    	 



    




11.12    
Confidentiality. Agent and Lender acknowledge that certain items of Collateral and information provided to Agent
and Lender by Borrower are confidential and proprietary information of Borrower, if and to the extent such information either (x)
is marked as confidential by Borrower at the time of disclosure, or (y) should reasonably be understood to be confidential (the
“Confidential Information”). Accordingly, Agent and Lender agree that any Confidential Information it may obtain in
the course of acquiring, administering, or perfecting Agent’s security interest in the Collateral shall not be disclosed
to any other Person or entity in any manner whatsoever, in whole or in part, without the prior written consent of Borrower, except
that Agent and Lender may disclose any such information: (a) to its own directors, officers, employees, accountants, counsel
and other professional advisors and to its affiliates if Agent or Lender in their sole discretion determines that any such party
should have access to such information in connection with such party’s responsibilities in connection with the Loan or this
Agreement and, provided that such recipient of such Confidential Information either (i) agrees to be bound by the confidentiality
provisions of this paragraph or (ii) is otherwise subject to confidentiality restrictions that reasonably protect against the disclosure
of Confidential Information; (b) if such information is generally available to the public; (c) if required in any report,
statement or testimony submitted to any governmental authority having or claiming to have jurisdiction over Agent or Lender; (d) if
required in response to any summons or subpoena or in connection with any litigation, to the extent permitted or deemed advisable
by Agent’s or Lender’s counsel; (e) to comply with any legal requirement or law applicable to Agent or Lender;
(f) to the extent reasonably necessary in connection with the exercise of any right or remedy under any Loan Document, including
Agent’s sale, lease, or other disposition of Collateral after default; (g) to any participant or assignee of Agent or
Lender or any prospective participant or assignee; provided, that such participant or assignee or prospective participant or assignee
agrees in writing to be bound by this Section prior to disclosure; or (h) otherwise with the prior consent of Borrower; provided,
that any disclosure made in violation of this Agreement shall not affect the obligations of Borrower or any of its affiliates or
any guarantor under this Agreement or the other Loan Documents.


 


11.13    
 Assignment of Rights. Subject to the provisions of Section 11.7, Borrower acknowledges and understands that
Agent or Lender may sell and assign all or part of its interest hereunder and under the Loan Documents to any Person or entity
(an “Assignee”). After such assignment the term “Agent” or “Lender” as used in the Loan Documents
shall mean and include such Assignee, and such Assignee shall be vested with all rights, powers and remedies of Agent and Lender
hereunder with respect to the interest so assigned; but with respect to any such interest not so transferred, Agent and Lender
shall retain all rights, powers and remedies hereby given. No such assignment by Agent or Lender shall relieve Borrower of any
of its obligations hereunder. Lender agrees that in the event of any transfer by it of the Note(s)(if any), it will endorse thereon
a notation as to the portion of the principal of the Note(s), which shall have been paid at the time of such transfer and as to
the date to which interest shall have been last paid thereon.


 


11.14    
Revival of Secured Obligations. This Agreement and the Loan Documents shall remain in full force and effect and
continue to be effective if any petition is filed by or against Borrower for liquidation or reorganization, if Borrower becomes
insolvent or makes an assignment for the benefit of creditors, if a receiver or trustee is appointed for all or any significant
part of Borrower’s assets, or if any payment or transfer of Collateral is recovered from Agent or Lender. The Loan Documents
and the Secured Obligations and Collateral security shall continue to be effective, or shall be revived or reinstated, as the case
may be, if at any time payment and performance of the Secured Obligations or any transfer of Collateral to Agent, or any part thereof
is rescinded, avoided or avoidable, reduced in amount, or must otherwise be restored or returned by, or is recovered from, Agent,
Lender or by any obligee of the Secured Obligations, whether as a “voidable preference,” “fraudulent conveyance,”
or otherwise, all as though such payment, performance, or transfer of Collateral had not been made. In the event that any payment,
or any part thereof, is rescinded, reduced, avoided, avoidable, restored, returned, or recovered, the Loan Documents and the Secured
Obligations shall be deemed, without any further action or documentation, to have been revived and reinstated except to the extent
of the full, final, and indefeasible payment to Agent or Lender in Cash.


 


11.15    
Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any
number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed
an original, but all of which counterparts shall constitute but one and the same instrument.


 



    	21



    	 



    




11.16    
No Third Party Beneficiaries. No provisions of the Loan Documents are intended, nor will be interpreted, to provide
or create any third-party beneficiary rights or any other rights of any kind in any Person other than Agent, Lender and Borrower
unless specifically provided otherwise herein, and, except as otherwise so provided, all provisions of the Loan Documents will
be personal and solely among Agent, Lender and Borrower.


 


11.17    
Agency.


 


(a)                
Lender hereby irrevocably appoints Hercules Technology Growth Capital, Inc. to act on its behalf as Agent hereunder and
under the other Loan Documents and authorizes Agent to take such actions on its behalf and to exercise such powers as are delegated
to Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto.


 


(b)                
Lender agrees to indemnify Agent in its capacity as such (to the extent not reimbursed by Borrower and without limiting
the obligation of Borrower to do so), according to its respective Term Commitment percentages (based upon the total outstanding
Term Loan Commitments) in effect on the date on which indemnification is sought under this Section 11.17, from and against any
and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any
kind whatsoever that may at any time be imposed on, incurred by or asserted against Agent in any way relating to or arising out
of, this Agreement, any of the other Loan Documents or any documents contemplated by or referred to herein or therein or the transactions
contemplated hereby or thereby or any action taken or omitted by Agent under or in connection with any of the foregoing; The agreements
in this Section shall survive the payment of the Loans and all other amounts payable hereunder.


 


(c)                
Agent in Its Individual Capacity. The Person serving as Agent hereunder shall have the same rights and powers in its capacity
as a Lender as any other Lender and may exercise the same as though it were not Agent and the term “Lender” shall,
unless otherwise expressly indicated or unless the context otherwise requires, include each such Person serving as Agent hereunder
in its individual capacity.


 


(d)                
Exculpatory Provisions. Agent shall have no duties or obligations except those expressly set forth herein and in the other
Loan Documents. Without limiting the generality of the foregoing, Agent shall not:


 


1.           be subject to any fiduciary
or other implied duties, regardless of whether any default or any Event of Default has occurred and is continuing;


 


2.           have any duty to take any
discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby
or by the other Loan Documents that Agent is required to exercise as directed in writing by Lender, provided that Agent shall not
be required to take any action that, in its opinion or the opinion of its counsel, may expose Agent to liability or that is contrary
to any Loan Document or applicable law; and


 


3.           except as expressly set forth
herein and in the other Loan Documents, have any duty to disclose, and Agent shall not be liable for the failure to disclose, any
information relating to Borrower or any of its affiliates that is communicated to or obtained by any Person serving as Agent or
any of its affiliates in any capacity.


 


(e)                
Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the request of Lender or as
Agent shall believe in good faith shall be necessary, under the circumstances or (ii) in the absence of its own gross negligence
or willful misconduct.


 



    	22



    	 



    




(f)                 
Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation
made in or in connection with this Agreement or any other Loan Document, (ii) the contents of any certificate, report or other
document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of
the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any default or Event of
Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other
agreement, instrument or document or (v) the satisfaction of any condition set forth in Section 4 or elsewhere herein, other than
to confirm receipt of items expressly required to be delivered to Agent.


 


(g)                
Reliance by Agent. Agent may rely, and shall be fully protected in acting, or refraining to act, upon, any resolution, statement,
certificate, instrument, opinion, report, notice, request, consent, order, bond or other paper or document that it has no reason
to believe to be other than genuine and to have been signed or presented by the proper party or parties or, in the case of cables,
telecopies and telexes, to have been sent by the proper party or parties. In the absence of its gross negligence or willful misconduct,
Agent may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon any
certificates or opinions furnished to Agent and conforming to the requirements of the Loan Agreement or any of the other Loan Documents.
Agent may consult with counsel, and any opinion or legal advice of such counsel shall be full and complete authorization and protection
in respect of any action taken, not taken or suffered by Agent hereunder or under any Loan Documents in accordance therewith. Agent
shall have the right at any time to seek instructions concerning the administration of the Collateral from any court of competent
jurisdiction. Agent shall not be under any obligation to exercise any of the rights or powers granted to Agent by this Agreement,
the Loan Agreement and the other Loan Documents at the request or direction of Lenders unless Agent shall have been provided by
Lender with adequate security and indemnity against the costs, expenses and liabilities that may be incurred by it in compliance
with such request or direction.


 


11.18    
Publicity.


 


(a)                
Borrower consents to the publication and use by Agent or Lender and any of its member businesses and affiliates the following
items and information, to the extent such items and information are already contained in any regular, periodic or special reports
or registration statements that Borrower files with the Securities and Exchange Commission or otherwise contained in any press
release or publicly available investor presentation made available on the Borrower’s website, and provided that such items
and information as depicted, described or otherwise used by Agent or Lender are done so in a manner consistent with such reports
or registration statements wherein the items or information are found: (i) Borrower’s name (including a brief description of the
relationship among Borrower, Agent and Lender) and logo and a hyperlink to Borrower’s web site, separately or together, in
written and oral presentations, advertising, promotional and marketing materials, client lists, public relations materials or on
its web site (together, the “Lender Publicity Materials”); (ii) the names of officers of Borrower in the Lender Publicity
Materials; and (iii) Borrower’s name, trademarks or servicemarks in any news release concerning Agent or Lender.


 


(b)                
Neither Borrower nor any of its member businesses and affiliates shall, without Agent’s and Lender’s consent,
publicize or use (i) Agent’s or Lender’s name (including a brief description of the relationship among Borrower, Agent and
Lender), logo or hyperlink to Agent’s or Lender’s web site, separately or together, in written and oral presentations,
advertising, promotional and marketing materials, client lists, public relations materials or on its web site (together, the “Borrower
Publicity Materials”); (ii) the names of officers of Agent or Lender in the Borrower Publicity Materials; and (iii) Agent’s
or Lender’s name, trademarks, servicemarks in any news release concerning Borrower; provided that notwithstanding anything
in the foregoing to the contrary, Borrower may use Lender’s and/or Agent’s name in connection with (x) any regular,
periodic and special reports or registration statements that Borrower files with the Securities and Exchange Commission or any
governmental authority that may be substituted therefor, or any national securities exchange, or (y) in any public or private offering
materials or other investor relations information produced by Borrower (including a brief description of the relationship among
Borrower, Agent and Lender).


 


(SIGNATURES TO FOLLOW)


 



    	23



    	 



    




IN WITNESS WHEREOF,
Borrower, Agent and Lender have duly executed and delivered this Loan and Security Agreement as of the day and year first above
written.


 


	 	BORROWER:
	 	EDGE THERAPEUTICS, INC.
	 	Signature:	/s/Brian A. Leuthner
	 	Print Name:	Brian A. Leuthner
	 	Title:	President and Chief Executive Officer
	Accepted in Palo Alto, California:	 	 
	 	AGENT:
	 	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
	 	Signature:	/s Ben Barg
	 	Print Name:	Ben Barg
	 	Title:	Senior Counsel
	 	LENDER:
	 	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
	 	Signature:	/s Ben Barg
	 	Print Name:	Ben Barg
	 	Title:	Senior Counsel



 



    	24



    	 



    




Table of Exhibits and Schedules


 


	Exhibit A:	Advance Request
	 	Attachment to Advance Request
	Exhibit B:	Promissory Note
	Exhibit C:	Name, Locations, and Other Information for Borrower
	Exhibit D:	Borrower’s Patents, Trademarks, Copyrights
and Licenses
	Exhibit E:	Borrower’s Deposit Accounts and Investment
Accounts
	Exhibit F:	Compliance Certificate
	Exhibit G:	Joinder Agreement
	Exhibit H:	ACH Debit Authorization Agreement
	Schedule 1	Subsidiaries
	Schedule 1.1	Commitments
	Schedule 1A	Existing Permitted Indebtedness
	Schedule 1B	Existing Permitted Investments
	Schedule 1C	Existing Permitted Liens
	Schedule 5.3	Consents, Etc.
	Schedule 5.5	Actions Before Governmental Authorities
	Schedule 5.8	Tax Matters
	Schedule 5.9	Intellectual Property Claims
	Schedule 5.10	Intellectual Property
	Schedule 5.11	Borrower Products
	Schedule 5.14	Capitalization



 



    	25



    	 



    




EXHIBIT
A


 


ADVANCE
REQUEST


 


	To:	Agent:	Date:	__________, 2014
	 	Hercules Technology Growth Capital, Inc.
(the “Agent”)	 	 
	 	400 Hamilton Avenue, Suite 310	 	 
	 	Palo Alto, CA 94301	 	 
	 	Facsimile: 650-473-9194	 	 
	 	Attn:	 	 



Edge Therapeutics, Inc. (“Borrower”) hereby requests
from Hercules Technology Growth Capital, Inc. (“Lender”) an Advance in the amount of _____________________ Dollars
($________________) on ______________, _____ (the “Advance Date”) pursuant to the Loan and Security Agreement among
Borrower, Agent and Lender (the “Agreement”). Capitalized words and other terms used but not otherwise defined herein
are used with the same meanings as defined in the Agreement.


Please:


	 	(a)	Issue a check payable to Borrower	 	 	 
	 	 	or	 	 	 
	 	(b)	Wire Funds to Borrower’s account	 	 	 
	 	 	Bank:	 	 	 
	 	 	Address:	 	 	 
	 	 	 	 	 	 
	 	 	ABA Number:	 	 	 
	 	 	Account Number:	 	 	 
	 	 	Account Name:	 	 	 



Borrower represents
that the conditions precedent to the Advance set forth in the Agreement are satisfied and shall be satisfied upon the making of
such Advance, including but not limited to: (i) that no event that has had or could reasonably be expected to have a Material
Adverse Effect has occurred and is continuing; (ii) that the representations and warranties set forth in the Loan Documents
are and shall be true and correct in all material respects on and as of the Advance Date with the same effect as though made on
and as of such date, except to the extent such representations and warranties expressly relate to an earlier date; (iii) that
Borrower is in compliance with all the terms and provisions set forth in each Loan Document on its part to be observed or performed;
and (iv) that as of the Advance Date, no fact or condition exists that would (or would, with the passage of time, the giving
of notice, or both) constitute an Event of Default under the Loan Documents. Borrower understands and acknowledges that Agent has
the right to review the financial information supporting this representation and, based upon such review in its sole discretion,
Lender may decline to fund the requested Advance.


 


Borrower hereby represents
that Borrower’s corporate status and locations have not changed since the date of the Agreement or, if the Attachment to
this Advance Request is completed, are as set forth in the Attachment to this Advance Request.


 


Borrower agrees to
notify Agent promptly before the funding of the Loan if any of the matters which have been represented above shall not be true
and correct on the Borrowing Date and if Agent has received no such notice before the Advance Date then the statements set forth
above shall be deemed to have been made and shall be deemed to be true and correct as of the Advance Date.


 


Executed as of [          ],
2014.


 


	 	BORROWER: EDGE THERAPEUTICS, INC.
	 	SIGNATURE:	 
	 	TITLE:	 
	 	PRINT NAME:	 



 



    	26



    	 



    




ATTACHMENT
TO ADVANCE REQUEST


 


Dated: _______________________


 


Borrower hereby represents and warrants to Agent that Borrower’s
current name and organizational status is as follows:


 


		Name:	Edge Therapeutics, Inc.
	 	Type of organization:	Corporation
	 	State of organization:	Delaware
	 	Organization file number:	 



 


Borrower hereby represents and warrants to Agent that the street
addresses, cities, states and postal codes of its current locations are as follows:


 



    	27



    	 



    




EXHIBIT
B


 


PROMISSORY
NOTE


 


	$[  ],000,000	Advance Date:  ___ __, 20[  ]
	 	Maturity Date:  _____ ___, 20[ ]


 


FOR VALUE RECEIVED, Edge Therapeutics, Inc.,
a Delaware corporation, for itself and each of its Subsidiaries (the “Borrower”) hereby promises to pay to the order
of Hercules Technology Growth Capital, Inc., a Maryland corporation or the holder of this Note (the “Lender”) at 400
Hamilton Avenue, Suite 310, Palo Alto, CA 94301 or such other place of payment as the holder of this Secured Term Promissory Note
(this “Promissory Note”) may specify from time to time in writing, in lawful money of the United States of America,
the principal amount of [ ] Million Dollars ($[ ],000,000) or such other principal amount as Lender has advanced to Borrower, together
with interest at a floating per annum rate equal to the Term Loan Interest Rate (as defined in the Loan Agreement (as defined below)).


 


This Promissory Note is the Note referred
to in, and is executed and delivered in connection with, that certain Loan and Security Agreement dated [          ], 2014, by and among
Borrower, Hercules Technology Growth Capital, Inc., a Maryland corporation (the “Agent”) and the several banks and
other financial institutions or entities from time to time party thereto as lender (as the same may from time to time be amended,
modified or supplemented in accordance with its terms, the “Loan Agreement”), and is entitled to the benefit and security
of the Loan Agreement and the other Loan Documents (as defined in the Loan Agreement), to which reference is made for a statement
of all of the terms and conditions thereof. All payments shall be made in accordance with the Loan Agreement. All terms defined
in the Loan Agreement shall have the same definitions when used herein, unless otherwise defined herein. An Event of Default under
the Loan Agreement shall constitute a default under this Promissory Note.


 


Borrower waives presentment and demand for
payment, notice of dishonor, protest and notice of protest under the UCC or any applicable law. Borrower agrees to make all payments
under this Promissory Note without setoff, recoupment or deduction and regardless of any counterclaim or defense. This Promissory
Note has been negotiated and delivered to Lender and is payable in the State of California. This Promissory Note shall be governed
by and construed and enforced in accordance with, the laws of the State of California, excluding any conflicts of law rules or
principles that would cause the application of the laws of any other jurisdiction.


 


BORROWER FOR ITSELF AND

ON BEHALF OF ITS SUBSIDIARIES:    [                    ]


 


	 	By:
	 	Title:



 



    	28



    	 



    




EXHIBIT
C


 


NAME, LOCATIONS,
AND OTHER INFORMATION FOR BORROWER


 


1. Borrower represents
and warrants to Agent that Borrower’s current name and organizational status as of the Closing Date is as follows:


 


		Name:	Edge Therapeutics, Inc.
	 	 	 
	 	Type of organization:	Corporation
	 	 	 
	 	State of organization:	Delaware
	 	 	 
	 	Organization
file number:	4647596



 


2. Borrower represents
and warrants to Agent that for five (5) years prior to the Closing Date, Borrower did not do business under any other name or organization
or form except the following:


 


Name:

Used during dates of:

Type of Organization:

State of organization:

Organization file Number:


 


Borrower’s fiscal year ends on December 31.

Borrower’s federal employer tax identification number is: 26-4231384.


 


3. Borrower represents
and warrants to Agent that its chief executive office is located at 200 Connell Drive, Suite 1600, Berkeley Heights, NJ 07922.


 



    	29



    	 



    




EXHIBIT
D


 


BORROWER’S
PATENTS, TRADEMARKS, COPYRIGHTS AND LICENSES


 


On
file with lender


 



    	30



    	 



    




EXHIBIT
E


 


BORROWER’S
DEPOSIT ACCOUNTS AND INVESTMENT ACCOUNTS


 


on
file with lender


 



    	31



    	 



    




EXHIBIT
F


 


COMPLIANCE
CERTIFICATE


 


Hercules Technology Growth Capital, Inc. (as “Agent”)

400 Hamilton Avenue, Suite 310

Palo Alto, CA 94301


 


Reference is made to
that certain Loan and Security Agreement dated [          ], 2014 and all ancillary documents entered into in connection with such Loan
and Security Agreement all as may be amended from time to time, (hereinafter referred to collectively as the “Loan Agreement”)
by and among Hercules Technology Growth Capital, Inc. (the “Agent”), the several banks and other financial institutions
or entities from time to time party thereto (collectively, the “Lender”) and Hercules Technology Growth Capital, Inc.,
as agent for the Lender (the “Agent”) and Edge Therapeutics, Inc. (the “Borrower”) as Borrower. All capitalized
terms not defined herein shall have the same meaning as defined in the Loan Agreement.


 


The undersigned is
an Officer of the Borrower, knowledgeable of all Borrower financial matters, and is authorized to provide certification of information
regarding the Borrower; hereby certifies that in accordance with the terms and conditions of the Loan Agreement, the Borrower is
in compliance for the period ending ___________ of all covenants, conditions and terms and hereby reaffirms that all representations
and warranties contained therein are true and correct on and as of the date of this Compliance Certificate with the same effect
as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier
date, after giving effect in all cases to any standard(s) of materiality contained in the Loan Agreement as to such representations
and warranties. Attached are the required documents supporting the above certification. The undersigned further certifies that
these are prepared in accordance with GAAP (except (i) for the absence of footnotes with respect to unaudited financial statements,
(ii) that they are subject to normal year end adjustments, and (iii) they do not contain certain non-cash items that are customarily
included in quarterly and annual financial statements) and are consistent from one period to the next except as explained below.


 


	REPORTING REQUIREMENT	REQUIRED	CHECK IF ATTACHED
	Interim Financial Statements 	Monthly within 30 days	 
	Interim Financial Statements 	Quarterly within 40 days	 
	Audited Financial Statements 	FYE within 150 days	 


 


	 	Very Truly Yours,
	 	EDGE THERAPEUTICS, INC.
	 	By:	 
	 	Name:	 
	 	Its:	 



 



    	32



    	 



    




EXHIBIT
G


 


FORM OF
JOINDER AGREEMENT


 


This Joinder Agreement
(the “Joinder Agreement”) is made and dated as of [          ], 20[    ], and is entered into by and between__________________.,
a ___________ corporation (“Subsidiary”), and HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation (as
“Agent”).


 


RECITALS


 


A. Subsidiary’s
Affiliate, EDGE THERAPEUTICS, INC., a Delaware corporation (“Borrower”) [has entered/desires to enter] into that certain
Loan and Security Agreement dated [ ], 20[ ], with the several banks and other financial institutions or entities from time to
time party thereto as lender (collectively, the “Lender”) and Agent, as such agreement may be amended (the “Loan
Agreement”), together with the other agreements executed and delivered in connection therewith;


 


B. Subsidiary acknowledges
and agrees that it will benefit both directly and indirectly from Borrower’s execution of the Loan Agreement and the other
agreements executed and delivered in connection therewith;


 


AGREEMENT


 


NOW THEREFORE, Subsidiary
and Agent agree as follows:


 


		1.	The recitals set forth above are incorporated into and made part of this Joinder Agreement. Capitalized
terms not defined herein shall have the meaning provided in the Loan Agreement.



 


		2.	By signing this Joinder Agreement, Subsidiary shall be bound by the terms and conditions of the
Loan Agreement the same as if it were the Borrower (as defined in the Loan Agreement) under the Loan Agreement, mutatis mutandis,
provided however, that (a) with respect to (i) Section 5.1 of the Loan Agreement, Subsidiary represents that it is an entity duly
organized, legally existing and in good standing under the laws of [          ], (b) neither Agent nor Lender shall have any duties, responsibilities
or obligations to Subsidiary arising under or related to the Loan Agreement or the other agreements executed and delivered in connection
therewith, (c) that if Subsidiary is covered by Borrower’s insurance, Subsidiary shall not be required to maintain separate
insurance or comply with the provisions of Sections 6.1 and 6.2 of the Loan Agreement, and (d) that as long as Borrower satisfies
the requirements of Section 7.1 of the Loan Agreement, Subsidiary shall not have to provide Agent separate Financial Statements.
To the extent that Agent or Lender has any duties, responsibilities or obligations arising under or related to the Loan Agreement
or the other agreements executed and delivered in connection therewith, those duties, responsibilities or obligations shall flow
only to Borrower and not to Subsidiary or any other Person or entity. By way of example (and not an exclusive list): (i) Agent’s
providing notice to Borrower in accordance with the Loan Agreement or as otherwise agreed among Borrower, Agent and Lender shall
be deemed provided to Subsidiary; (ii) a Lender’s providing an Advance to Borrower shall be deemed an Advance to Subsidiary;
and (iii) Subsidiary shall have no right to request an Advance or make any other demand on Lender.



 


		3.	Subsidiary agrees not to certificate its equity securities without Agent’s prior written
consent, which consent may be conditioned on the delivery of such equity securities to Agent in order to perfect Agent’s
security interest in such equity securities.



 


		4.	Subsidiary acknowledges that it benefits, both directly and indirectly, from the Loan Agreement,
and hereby waives, for itself and on behalf on any and all successors in interest (including without limitation any assignee for
the benefit of creditors, receiver, bankruptcy trustee or itself as debtor-in-possession under any bankruptcy proceeding) to the
fullest extent provided by law, any and all claims, rights or defenses to the enforcement of this Joinder Agreement on the basis
that (a) it failed to receive adequate consideration for the execution and delivery of this Joinder Agreement or (b) its obligations
under this Joinder Agreement are avoidable as a fraudulent conveyance.



 


[REMAINDER OF PAGE INTENTIONALLY
LEFT BLANK]


 



    	33



    	 



    




[SIGNATURE PAGE TO JOINDER
AGREEMENT]


 


SUBSIDIARY:


 


_________________________________.


 


	 	By:	 	 
	 	Name:	 	 
	 	Title:	 	 
	 	 	 	 
	 	Address:	 	 
	 	 	 	 
	 	Telephone:	 	 
	 	Facsimile:	 	 



 


AGENT:


 


HERCULES TECHNOLOGY GROWTH CAPITAL,
INC.



By:____________________________________

Name:__________________________________

Title: ___________________________________



Address:

400 Hamilton Ave., Suite 310

Palo Alto, CA 94301

Facsimile: 650-473-9194

Telephone: 650-289-3060


 



    	34



    	 



    




EXHIBIT
H


 


ACH DEBIT
AUTHORIZATION AGREEMENT


 


Hercules Technology Growth Capital, Inc.

400 Hamilton Avenue, Suite 310

Palo Alto, CA 94301


 


               Re:Loan and Security Agreement dated
_______________ between Edge Therapeutics, Inc. (“Borrower”) and Hercules Technology Growth Capital, Inc. (“Agent”)
(the “Agreement”)


 


In connection with the above referenced
Agreement, Borrower hereby authorizes Agent to initiate debit entries for the periodic payments due under the Agreement to Borrower’s
account indicated below. Borrower authorizes the depository institution named below to debit to such account.


 


	Depository
Name	Branch
	 	 
	City	State
and Zip Code
	 	 
	Transit/ABA
Number	Account
Number
	 	 



 



This authority will remain in full force
and effect so long as any amounts are due under the Agreement.


 


EDGE THERAPEUTICS, INC.


 


By: _________________________________________


 


Date: ________________________________________


 



    	35



    	 



    




Schedule
1


 


Subsidiaries


 


None.


 



    	36



    	 



    




SCHEDULE
1.1


 


COMMITMENTS


 


	LENDER	TERM COMMITMENT
	Hercules Technology Growth Capital, Inc.	$10,000,000
	TOTAL COMMITMENTS	$10,000,000



 



    	37



    	 



    




Schedule
1A


 


Existing
Permitted Indebtedness


 


None.


 



    	38



    	 



    




Schedule
1B


 


Existing
Permitted Investments


 


None.


 



    	39



    	 



    




Schedule
1C


 


Existing
Permitted Liens


 


None.


 



    	40



    	 



    




Schedule
5.3


 


Consents,
Etc.


 


None.


 



    	41



    	 



    




Schedule
5.5


 


Actions
Before Governmental Authorities


 


None.


 



    	42



    	 



    




Schedule
5.8


 


Tax
Matters


 


None.


 



    	43



    	 



    




Schedule
5.9


 


Intellectual
Property Claims


 


None.


 



    	44



    	 



    




Schedule
5.10


 


Intellectual
Property


 


None.


 



    	45



    	 



    




Schedule
5.11


 


Borrower
Products


 


None.


 



    	46



    	 



    




Schedule
5.14


 


Capitalization


 


1.Capitalization
of the Borrower as of August 26, 2014:


 


	Type of Security	Authorized Shares	Number of Shares Outstanding
	Common Stock, par value $0.00033 per share	17,500,000	2,310,000
	Series A Preferred Stock, par value $0.00033 per share	1,000,000	864,500
	Series B Preferred Stock, par value $0.00033 per share	2,500,000	2,415,116
	Series B-1 Preferred Stock, par value $0.00033 per share	500,000	359,935
	Series C Preferred Stock, par value $0.00033 per share	6,000,000	4,697,314



 


2.There are
no Subsidiaries.


 



    	47